The burgeoning landscape of emerging treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a similar https://shaniahquq651238.wikiusnews.com/1986447/retatrutide_vs_tirzepatide_a_comparative_analysis